Background: A 21-valent pneumococcal conjugate vaccine (PCV21) was recently authorized in Canada to protect adults against invasive pneumococcal disease (IPD).
Objective: To assess the cost-effectiveness of PCV21 compared to current Canadian vaccination recommendations for adults of different age and risk groups.
Methods: We used a static cohort model to estimate lifetime incremental cost-effectiveness ratios (ICERs), in 2023 Canadian dollars per quality-adjusted life year (QALY), discounted at 1.5 %, in population cohorts aged 33 (midpoint of the 18-49 year age group), 50, and 65 years from the health system and societal perspectives. The primary analysis used 2022 serotype distributions for IPD cases. Additional analyses incorporated indirect effects from pediatric vaccination and used IPD serotype distributions from 2015 to 2019, to explore the impact of changes over time observed in some age groups.
Results: For population groups currently recommended to receive PCV20 in Canada (65 years and older, 50-64 years with additional risk factors for IPD, or 18-49 years with immunocompromising conditions), PCV21 was cost-effective at a $50,000 per QALY threshold and dominated PCV20 in most scenarios when PCV21 serotypes were more prevalent. When PCV20 serotypes were equally or more prevalent than PCV21 serotypes, results were more sensitive to assumptions about indirect effects and serotype replacement. For groups not currently recommended a conjugate vaccine (50-64 years without additional IPD risk factors and 18-49 years with chronic medical conditions or unhoused populations), use of a higher-valency conjugate vaccine was a cost-effective intervention compared to no vaccination, with the optimal vaccine dependent on the proportion of IPD attributable to PCV20 and PCV21 serotypes in the population of interest. Results were sensitive to vaccine price in most scenarios.
Interpretation: The use of PCV21 may be cost-effective in some populations, depending on the prevalence of IPD serotypes covered by PCV20 and PCV21.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2025.126985 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Childhood invasive pneumococcal disease and acute otitis media in Central Greece during 2005-2024 - A report at the doorstep of the new multivalent PCV era.
Vaccine
March 2025
Department of Pediatrics, School of Medicine, University of Thessaly, Larissa, Greece. Electronic address:
Background: In Greece, pneumococcal conjugate vaccines (PCVs) became sequentially available: 7-valent in October 2004, 10-valent in May 2009, 13-valent in June 2010 and 15-valent in March 2023; soon after availability all vaccines were incorporated in the National Ιmmunization Program except for PCV7 which was implemented in January 2006. Since July 2010, PCV13 has been the most commonly used PCV. Surveillance at a regional and a national level is a valuable tool to monitor the impact of PCVs.
View Article and Find Full Text PDFHigh Mortality Due to Pneumococcal Meningitis in Children With Sickle Cell Disease: A French Multicenter Observational Study From 2001 to 2021.
Pediatr Infect Dis J
March 2025
From the Pediatrics Department, Jean Verdier Hospital, Assistance Publique-Hôpitaux de Paris, Bondy, France.
Background: Sickle cell disease (SCD) predisposes children to bacterial infections, particularly invasive pneumococcal disease. Pneumococcal immunization associated with antibiotic prophylaxis reduced the incidence of invasive pneumococcal disease in these patients. However, the risk remains higher than in the general population.
View Article and Find Full Text PDFThe vaccine dosing effect overcomes the reduced immunogenic potential and in vivo efficacy of 33F pneumococcal serotype.
Vaccine
March 2025
Dept of Oral Biology, College of Dentistry, University of Florida, Gainesville, FL, USA; Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USA. Electronic address:
Serotype 33F is an emerging Streptococcus pneumoniae (Spn) serotype associated with asymptomatic nasopharyngeal (NP) colonization and invasive pneumococcal disease (IPD). Serotype 33F is a component in the advanced version of the pneumococcal conjugate vaccine 15 (PCV 15) formulation. However, in the murine vaccination model, serotype 33F exhibits reduced immunogenicity, correlating with reduced protection against 33F.
View Article and Find Full Text PDFCost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada.
Vaccine
March 2025
Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Background: A 21-valent pneumococcal conjugate vaccine (PCV21) was recently authorized in Canada to protect adults against invasive pneumococcal disease (IPD).
Objective: To assess the cost-effectiveness of PCV21 compared to current Canadian vaccination recommendations for adults of different age and risk groups.
Methods: We used a static cohort model to estimate lifetime incremental cost-effectiveness ratios (ICERs), in 2023 Canadian dollars per quality-adjusted life year (QALY), discounted at 1.
SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.
Vaccine
March 2025
Viral Vaccines R&D, Inventprise, Inc., Redmond, WA, USA. Electronic address:
The SARS-CoV-2 pandemic necessitated effective vaccines that can endure antigenic mutations. Here we demonstrate highly immunogenic conjugate vaccines that elicit broad cross-neutralization to variants of concern (VOC) in animal studies. By utilizing protein-protein conjugation and Toll-Like Receptor (TLR) agonist adjuvants we achieve enhanced immunogenicity compared to unconjugated equivalents.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!